Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab

Clinical and Experimental Rheumatology

Volumn 33, Issue , 2015, Pages 160-167

  Fraticelli, Paolo ^a   De Vita, Salvatore ^b   Franzolini, Nicoletta ^b   Svegliati, Silvia ^c   Scott, Caterina A ^d   Tonnini, Cecilia ^c   Spadoni, Tatiana ^c   Gabrielli, Barbara ^c   Pomponio, Giovanni ^a   Moroncini, Gianluca ^a,c   Gabrielli, Armando ^a,c  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF UDINE   (Italy)

Author keywords

Autoimmune disease; B cells; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; COLCHICINE; COLLAGEN TYPE 1; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; ILOPROST; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; PDGF RECEPTOR ANTIBODY; PENICILLAMINE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; PLATELET DERIVED GROWTH FACTOR RECEPTOR;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; B LYMPHOCYTE; BIOLOGICAL ACTIVITY; CELL ACTIVATION; CLINICAL ARTICLE; DISEASE SEVERITY; DOWN REGULATION; FEMALE; FIBROBLAST; GENE EXPRESSION; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PRIORITY JOURNAL; RODNAN SKIN SCORE; SCLERODERMA; SCORING SYSTEM; SKIN BIOPSY; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TYPE I COLLAGEN GENE; VISUAL ANALOG SCALE; WELLBEING; YOUNG ADULT; BLOOD; CELL CULTURE; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FIBROSIS; GENETICS; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; ITALY; METABOLISM; MULTICENTER STUDY; PATHOLOGY; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; TIME; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AUTOANTIBODIES; B-LYMPHOCYTES; CELLS, CULTURED; COLLAGEN TYPE I; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLASTS; FIBROSIS; HOSPITALS, UNIVERSITY; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; ITALY; MALE; MIDDLE AGED; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946208789     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. GABRIELLI A, AVVEDIMENTO EV, KRIEG T: Scleroderma. N Engl J Med 2009; 360: 1989-2003.
2. JIMENEZ SA, DERK CT: Following the molecular pathway toward an understanding of the pathogenesis of systemic sclerosis Ann Inter Med 2004; 140: 37-50.
3. VARGA J, ABRAHAM D: Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
4. FRATICELLI P, GABRIELLI B, POMPONIO G et al.: Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther 2014; 16: R144.
5. NIHTYANOVA SI, ONG VH, DENTON CP: Current management strategies for systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl. 81): 156-64.
6. WHITFIELD MI, FINLAY DR, MURRAY JI et al.: Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003; 100: 12319-24.
7. SATO S, FUJIMOTO M, HASEGAWA M, TAKEHARA K: Altered blood B lymphocyte homeostasis in Systemic sclerosis. Expanded naïve B cells and diminished but activated memory B cells. Arthritis Rheum 2004; 50: 1918-27.
8. MATSUSHITA T, HASEGAWA M, YANABA K KODERA M, TAKEHARA K, SATO S: Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192-01.
9. DUNCAN MR, BERMAN B: Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991; 97: 686-92.
10. VARGA J, ROSENBLOOM J, JIMENEZ SA: Transforming growth factor β (TGFβ) causes a persistent increase in steady-state amounts of type I and III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987; 297: 597-04.
11. RINCON M, ANGUITA J, NAKAMURA T FIKRIG E, FLAVELL RA: Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med 1997; 185: 461-9.
12. GABRIELLI A, SVEGLIATI S, MORONCINI G, AVVEDIMENTO E: Pathogenic autoantibodies in systemic sclerosis. Curr Opin Immunol 2007; 19: 640-5.
13. LUNARDI C, BASON C, NAVONE R et al.: Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat Med 2000; 6: 1183-6.
14. BARONI SS, SANTILLO M, BEVILACQUA F et al.: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis (scleroderma). N Engl J Med 2006; 354: 2667-76.
15. FINESCHI S, GOFFIN L, REZZONICO R et al.: Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum 2008; 58: 3913-23.
16. RIEMEKASTEN G, PHILIPPE A, NATHER M et al.: Involvement of functional autoantibodies against vascular receptors in systemic sclerosis. Ann Rheum Dis 2011; 70: 530-6.
17. AVOUAC J, ALLANORE Y: Targeted immunotherapies in systemic sclerosis. Clin Exp Rheumatol 2014; 32 (Suppl. 81): 165-72.
18. GLENNIE MJ, FRENCH RR, CRAGG MS, TAYLOR PP: Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44: 3823-37.
19. WEINER GJ: Rituximab: mechanism of action. Semin Hematol 2010; 47: 115-23.
20. SAITO E, FUJIMOTO M, HASEGAWA M et al.: CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. J Clin Invest 2002; 109: 1453-62.
21. BOSELLO S, De SANTIS M, LAMA G et al.: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
22. SMITH V, van PRAET JT, VANDOOREN B et al.: Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis 2010; 69: 193-7.
23. DAOUSSIS D, LIOSSIS SN, TSAMANDAS AC et al.: Experience with rituximab in scleroderma: results from 1-year, proof-of-principle study. Rheumatology 2010; 49: 271-80.
24. DAOUSSIS D, TSAMANDAS AC, LIOSSIS SN et al.: B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin. Arthritis Res Ther 2012; 14: R145.
25. DAOUSSIS D, LIOSSIS SN, TSAMANDAS AC et al.: Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol 2012; 30 (Suppl. 71): S17-22.
26. SMITH V, PIETTE Y, van PRAET JT et al.: Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013; 40: 52-7.
27. Subcommitte for Scleroderma Ccriteria of the Aamerican RrheumatisSm AassSSociation DdiagnosStic and Ttherapeutic Ccommitee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthrtis Rheum 1980; 23: 581-90.
28. SVEGLIATI BARONI S, CANCELLO R, SAMBO P et al.: PDGF and reactive oxygen species (ROS) regulate Ras protein levels in primary human fibroblasts via ERK1/2. Amplification of ROS-ERK-Ras signalling in systemic sclerosis fibroblasts. J Biol Chem 2005; 280: 36474-82. .
29. SPADONI T, SVEGLIATI BARONI S, AMICO D et al.: A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol 2015; 67: 1611-22.
30. WHITE B, BAUER EA, GOLDSMITH LA et al.: Guidelines for clinical trials in systemic sclerosis (scleroderma). Arthritis Rheum 1995; 38: 351-60.
31. FURST DE, KHANNA D, MATUCCI-CERINIC M et al.: Scleroderma - developing measures of response. J Rheumatol 2005; 32: 2477-80.
32. FURST DE, CLEMENTS PJ, STEEN VD et al.: The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis. J Rheumatol 1998; 25: 84-8.
33. CLEMENTS P, LACHENBRUCH P, SIEBOLD J et al.: Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995; 22: 1281-5.
34. POOLE JL, STEEN VD: The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991; 4: 27-31.
35. Vvan den HOOGEN FHJ, BENZ D: Systemic sclerosis (diagnosis, differential diagnosis, evaluation of laboratory tests). In: HACHULLA E, CZIRJáK L (Eds.) Eular Textbook on Systemic Sclerosis. BMJ Publishing Group; 2013: 3-15.
36. AMICO D, SPADONI T, ROVINELLI M et al.: Intracellular free radical production by peripheral blood T lymphocytes from patients with systemic sclerosis: role of NADPH oxidase and ERK1/2. Arthritis Res Ther 2015; 17: 68.
37. SAMBO P, SVEGLIATI BARONI S, LUCHETTI M et al.: Oxidative stress in scleroderma. Maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 2001; 44: 2653-62.
38. LANDIS JR, KOCH GG: The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
39. JORDAN S, DISTLER JH, MAURER B et al.; on behalf of the EUeuSTARtar Rrituximab sStudy group: Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis 2015; 74: 1188-94.
40. LAFYATIS R, KISSIN E, YORK M et al.: B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60: 578-83.
41. HASEGAWA M: B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis. J Dermatol 2010; 37: 3-10.
42. KUWANA M, GABRIELLI A: Autoantibodies, autoimmunity. In: HACHULLA E, CZIRJá K L (Eds.) Eular Textbook on Systemic sclerosis. BMJ Publishing Group; 2013; 88-96.
43. CLASSEN JF, HENROHN D, RORSMAN F et al.: Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum 2009; 60: 1137-44.
44. LOIZOS N, LARICCIA L, WEINER J et al.: Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera. Arthritis Rheum 2009; 60: 1145-51.
45. KURASAWA K, ARAI S, OWADA T, MAEZAWA R, KUMANO K, FUKUDA T: Autoantibodies against platelet-derived growth factor receptor alpha in patients with systemic lupus erythematosus. Mod Rheumatol 2010; 20: 458-65.
46. GABRIELLI A, MORONCINI G, SVEGLIATI S, AVVEDIMENTO E: Autoantibodies against the platelet-derived growth factor receptor in scleroderma: comment on the articles by Classen et al. and Loizos et al. Arthritis Rheum 2009; 60: 3521-2.
47. MORONCINI G, GRIECO A, NACCI G et al.: Epitope specificity determines pathogenicity and detectability of anti-PDGFRa autoantibodies in systemic sclerosis. Arthritis Rheumatol 2015; 67: 1891-903.
48. HIEPE F, DöRNER T, HAUSER AE, HOYER BF, MEI H, RADBRUCH A: Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011; 7: 170-8.
49. GABRIELLI A, SVEGLIATI S, MORONCINI G, AMICO D: New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J 2012; 6: 87-95.
50. SMALDONE S, OLIVIERI J, GUSELLA GL, MORONCINI G, GABRIELLI A, RAMIREZ F: Ha-Ras stabilization mediates pro-fibrotic signals in dermal fibroblasts. Fibrogenesis Tissue Repair 2011; 4: 8.
51. SVEGLIATI S, MARRONE G, PEZONE A et al.: Oxidative DNA damage induces the ATM-mediated transcriptional suppression of the Wnt inhibitor WIF-1 in systemic sclerosis and fibrosis. Sci Signal 2014; 7: ra84.
52. CHUNG L, DENTON CP, DISTLER O, FURST DE, KHANNA D, MERKEL PA: Clinical trial design in scleroderma: where are we and where do we go next? Clin Exp Rheumatol 2012; 30 (Suppl. 71): S97-102.